TLDR
- CMS announced a finalized 2.48% Medicare Advantage payment rate for 2027, a dramatic improvement from the 0.09% figure initially proposed in January.
- Humana (HUM) spiked 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) climbed more than 6% during premarket hours.
- The revised rate will deliver approximately $13 billion in extra Medicare Advantage funding to insurers throughout 2027.
- Other healthcare stocks rallied alongside, including Molina Healthcare (MOH) gaining 7% and Centene (CNC) advancing 4%.
- Mizuho’s Jared Holz characterized the rate as “certainly better than the government’s initial rate decision,” while cautioning it’s not remarkable in isolation.
Humana (HUM) began Tuesday’s session approximately 11% higher following the Monday after-hours release of finalized Medicare Advantage reimbursement rates for 2027.
The confirmed 2.48% rate represents a substantial improvement over January’s preliminary 0.09% proposal, which blindsided the healthcare industry and triggered a selloff in insurance equities.
This CMS decision guarantees that private health insurance companies will receive over $13 billion in incremental Medicare Advantage reimbursements from federal sources during 2027.
UnitedHealth (UNH) and CVS Health (CVS), which owns Aetna, each advanced more than 6% before Tuesday’s opening bell. Elevance Health (ELV) rose roughly 5%. Hospital operators and managed care companies also experienced gains, with Molina Healthcare (MOH) jumping 7% and Centene (CNC) adding 4%.
The rally followed intensive advocacy efforts by insurers and industry associations, who contended that January’s proposal failed to account for escalating healthcare expenses. The Better Medicare Alliance had characterized the near-zero preliminary rate as effectively a “cut,” noting that medical cost inflation has been running between 7% and 9% annually.
What Changed in the Final Rate
CMS introduced multiple technical adjustments in conjunction with the primary rate announcement. Beginning in 2027, the organization will eliminate diagnosis information from unlinked chart review documentation when determining risk scores, though an exception will apply for beneficiaries transitioning between Medicare Advantage carriers.
The agency indicated this modification will disproportionately affect plans that depend extensively on chart reviews to document patient conditions and secure elevated reimbursements. CMS additionally refined the Part D risk adjustment framework to incorporate modifications mandated by the Inflation Reduction Act.
CMS Administrator Dr. Mehmet Oz stated the revisions seek to maintain “coverage affordable” while ensuring enrollees receive “real value from their plans.”
Wall Street analysts had maintained conservative expectations before Monday’s disclosure. TD Cowen’s Ryan Langston had anticipated a more moderate increase in the 1% to 1.5% range. The 2.48% result surpassed those projections, though Mizuho’s Jared Holz offered measured commentary: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”
Holz noted there is now “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”
The Stakes Behind the Rate
Medicare Advantage serves approximately 35 million enrollees and has experienced consistent expansion to exceed participation in traditional fee-for-service Medicare. The finalized rate determines the distribution of more than half a trillion dollars through private insurance plans annually, establishing it as among the most scrutinized metrics in the health insurance industry.
The rate incorporates elements including baseline cost trends, 2026 Star Ratings that determine quality incentive payments, and revisions to risk adjustment calculations. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment framework for 2027.
Bipartisan concerns about controlling Medicare Advantage expenditures had introduced unpredictability into the rate-setting process. Lawmakers from both parties have questioned insurer documentation methods that may generate elevated payments for patients with additional recorded conditions. The Biden administration’s CMS had already begun restricting those reimbursements, and January’s proposal under the Trump administration indicated ongoing regulatory attention.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
